Top News

Virobay Gets $8M In Additional Series B

Menlo Park-based Virobay, which is developing pharmaceuticals to treat neuropathic pain, autoimmune disease and fibrosis, has raised $8M in an additional, Series B funding

The story you have requested is only available to paid members of the silicontap.com web site. Stories newer than 15 days are restricted to paid members only. Please login in order to access this members-only content, or become a member.

 

Marketplace


blog comments powered by Disqus
 

Latest Headlines

Browse Issues